Login to Your Account



Earnings Roundup

Surge in Revlimid Sales Propels Celgene's Solid Second Quarter

By Jennifer Boggs


Friday, July 25, 2008
Celgene Corp.'s first full quarter following its March acquisition of Pharmion Corp. proved to be a strong one, as the Summit, N.J.-based firm reported "record" sales for its flagship multiple myeloma drug Revlimid and posted higher-than-expected second-quarter earnings. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription